Target intelligence / Profile preview

β-sheet protein aggregate (None in standard usage)

Target
None in standard usage
Molecular classification
Other (protein aggregate), Amyloid, Misfolded protein assembly; not an enzyme, receptor, or conventional molecular target
01

Overview

β-sheet protein aggregates are assemblies of misfolded proteins characterized by an extensive β-sheet structure, where β-strands run perpendicular to the fiber axis and are stabilized by interstrand hydrogen bonds. These aggregates are insoluble, highly stable, and resistant to degradation, forming fibrillar deposits known as amyloid. Formation typically occurs due to improper protein folding, mutations, or chemical modifications, and is associated with cytotoxicity and cell stress. β-sheet aggregates serve as pathological markers and therapeutic targets in diseases such as Alzheimer's, Parkinson's, and systemic amyloidoses. They are not unique molecular entities but represent a common structural motif in disease-related protein aggregation.

Other names
Amyloid fibrilscross-β aggregatesprotein amyloidmisfolded β-sheet aggregateamyloid protein aggregate
02

Mechanism of action

Antibodies/binders that promote clearance of aggregates Small molecules that inhibit aggregation or promote disaggregation Stabilization of native protein conformation to prevent misfolding Inhibition of nucleation/elongation of fibrils

03

Biological functions

Pathological protein aggregationDisruption of normal cellular homeostasisCytotoxicityInduction of cellular stress response
04

Disease associations

Neurodegenerative disease (Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, prion diseases)Systemic amyloidosisOther proteinopathies
05

Safety considerations

Immunological reactions (amyloid-related imaging abnormalities, ARIA)Off-target toxicity from aggregate clearancePossible adverse effects due to interference with physiological protein functionsBlood-brain barrier penetration challenges
06

Interacting drugs

Aducanumab (Alzheimer’s, anti-amyloid antibody)

3 more in the full profile.

07

Biomarkers

Amyloid-β levels in cerebrospinal fluid (CSF)Tau protein levels (Alzheimer's disease)PET imaging of amyloid depositsSerum transthyretin for TTR amyloidosis

Beyond the preview

Go deeper on β-sheet protein aggregate (None in standard usage).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on β-sheet protein aggregate (None in standard usage).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call